2002
DOI: 10.1001/archderm.138.10.1341
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
34
0

Year Published

2003
2003
2017
2017

Publication Types

Select...
4
3
3

Relationship

0
10

Authors

Journals

citations
Cited by 65 publications
(35 citation statements)
references
References 21 publications
1
34
0
Order By: Relevance
“…It has been reported that IL-10 administration could enhance IL-10 mRNA expression in the skin (60); however, two of seven patients relapsed before study termination after 4 mo (61). In the most comprehensive study, only a modest improvement (mean 35.6% improvement in PASI) peaking at 8 wk and rebound flares afterward have been reported (62). Expression levels of IL-10 in the psoriatic lesion and its change after therapies varied among reports.…”
Section: Discussionmentioning
confidence: 99%
“…It has been reported that IL-10 administration could enhance IL-10 mRNA expression in the skin (60); however, two of seven patients relapsed before study termination after 4 mo (61). In the most comprehensive study, only a modest improvement (mean 35.6% improvement in PASI) peaking at 8 wk and rebound flares afterward have been reported (62). Expression levels of IL-10 in the psoriatic lesion and its change after therapies varied among reports.…”
Section: Discussionmentioning
confidence: 99%
“…In a recent study (Kimball et al, 2002), 28 patients with moderate-to-severe psoriasis received rhIL-10 (20 g/kg) or placebo subcutaneously three times weekly for 12 weeks in a randomized, double-blind manner. Remarkably, treatment with rhIL-10 resulted in only temporary clinical improvement after 6 and 8 weeks, despite sustained systemic decreases in proinflammatory and type 1 cytokine production.…”
Section: E Therapy Of Psoriasismentioning
confidence: 99%
“…141Ϫ143 However, a larger randomized, doubleblind, placebo-controlled study in 28 patients demonstrated that IL-10 treatment results in only temporary improvements in disease, despite sustained decreases in systemic proinflammatory type 1 cytokine production. 144 Subcutaneous injections of IL-10 can cause decreases in monocytic HLA-DR expression, as well as a shift toward a type 2 cytokine pattern (i.e., increased proportion of IL-4-, IL-5-, and IL-10-producing T cells, and increases in IgE serum level). Clinical response to IL-10 in psoriasis has been correlated to decreased cutaneous cell infiltration and lesional expression of IFN-␥, TNF, IL-17, IL-8, and CXCR2.…”
Section: Il-10 In Inflammatory Cutaneous Disorders Psoriasismentioning
confidence: 99%